IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 51.613
EU - Europa 4.805
AS - Asia 3.479
SA - Sud America 55
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 27
AF - Africa 13
Totale 60.020
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 51.567
SG - Singapore 1.341
CN - Cina 1.309
UA - Ucraina 961
IE - Irlanda 771
DE - Germania 618
KR - Corea 549
IT - Italia 469
PL - Polonia 405
RU - Federazione Russa 385
FR - Francia 367
GB - Regno Unito 268
FI - Finlandia 233
SE - Svezia 186
HK - Hong Kong 107
NL - Olanda 40
CA - Canada 34
JP - Giappone 34
ID - Indonesia 29
BR - Brasile 25
IN - India 22
BE - Belgio 21
AU - Australia 17
A2 - ???statistics.table.value.countryCode.A2??? 15
ES - Italia 15
CL - Cile 14
EU - Europa 12
VN - Vietnam 12
GR - Grecia 11
MY - Malesia 11
NZ - Nuova Zelanda 11
CH - Svizzera 7
IL - Israele 7
IR - Iran 7
TR - Turchia 7
AT - Austria 6
CZ - Repubblica Ceca 6
EC - Ecuador 6
EG - Egitto 6
MX - Messico 6
RO - Romania 6
BD - Bangladesh 5
NO - Norvegia 5
PH - Filippine 5
PT - Portogallo 5
AR - Argentina 4
IQ - Iraq 4
MK - Macedonia 4
DK - Danimarca 3
EE - Estonia 3
HU - Ungheria 3
JO - Giordania 3
KH - Cambogia 3
PE - Perù 3
SA - Arabia Saudita 3
TW - Taiwan 3
UZ - Uzbekistan 3
CO - Colombia 2
CR - Costa Rica 2
DM - Dominica 2
ET - Etiopia 2
GT - Guatemala 2
KE - Kenya 2
LK - Sri Lanka 2
MD - Moldavia 2
NP - Nepal 2
PK - Pakistan 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
VE - Venezuela 1
Totale 60.020
Salva come PNG Salva come JPEG
Città #
Woodbridge 12.783
Wilmington 12.541
Houston 12.252
Fairfield 2.728
Ann Arbor 1.724
Ashburn 1.194
Singapore 1.146
Seattle 1.143
Chandler 922
Cambridge 888
Jacksonville 830
Dublin 691
Medford 528
Dearborn 461
Hangzhou 422
Kraków 403
Beijing 371
Santa Clara 286
Lawrence 240
New York 202
Zhengzhou 164
San Diego 135
Rome 133
Menlo Park 120
Hong Kong 102
Mülheim 83
Moscow 67
Redwood City 57
Norwalk 55
Milan 53
Mountain View 46
Boardman 42
Shanghai 41
London 39
Helsinki 38
Chicago 37
San Mateo 37
Detroit 36
Hefei 33
Verona 33
Nanjing 32
University Park 31
Palo Alto 28
Falls Church 27
Jakarta 27
Guangzhou 26
Kunming 26
Jinan 22
Saint Petersburg 22
Toronto 22
Brussels 20
Redmond 17
San Francisco 15
Naples 14
Los Angeles 13
San Jose 13
Hounslow 12
Phoenix 12
Wuhan 12
Council Bluffs 11
Nuremberg 11
Shenyang 11
Chengdu 10
Kilburn 10
La Veta 10
Munich 10
Seoul 10
Fuzhou 9
Hanoi 8
Indiana 8
Nanchang 8
Prescot 8
Athens 7
Washington 7
Giv‘atayim 6
Kuala Lumpur 6
Olomouc 6
São Paulo 6
Acerra 5
Amsterdam 5
Canberra 5
Caserta 5
Frankfurt am Main 5
Groningen 5
Hamilton 5
Hebei 5
Lappeenranta 5
Ningbo 5
Ottawa 5
Simi Valley 5
Taizhou 5
Tokyo 5
Xian 5
Auburn Hills 4
Berlin 4
Cagliari 4
Dong Ket 4
Durham 4
Jiaxing 4
Köln 4
Totale 53.762
Salva come PNG Salva come JPEG
Nome #
An update on the pharmacotherapeutic management of lower respiratory tract infections 493
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 464
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 462
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 461
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 456
Interaction between corticosteroids and muscarinic antagonists in human airways 455
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. 448
A systems medicine clinical platform for understanding and managing non- communicable diseases 448
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 447
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 441
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 438
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 437
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 436
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 433
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 429
Optimizing drug delivery in COPD: The role of inhaler devices 426
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 426
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 425
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 424
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 422
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 420
Asthma and comorbid medical illness. 419
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 419
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 419
Tiotropium formulations and safety: a network meta-analysis 417
Airflow obstruction: Is it asthma or is it COPD? 416
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 416
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 414
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 410
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 406
Asthma and comorbid medical illness 404
Role of muscarinic antagonists in asthma therapy 404
Bronchodilator therapy for chronic cough 402
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 399
The prevalence of asthma and COPD in Italy: a practice-based study 395
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 395
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 393
Metabolic syndrome and risk of pulmonary involvement 392
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 392
The Challenges of Precision Medicine in COPD 392
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 391
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 388
New Treatments for COPD in the Elderly 388
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 387
Umeclidinium for the treatment of chronic obstructive pulmonary disease 385
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 385
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 384
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 384
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 383
The effect of indacaterol during an acute exacerbation of COPD 383
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 382
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 380
Translational study searching for synergy between glycopyrronium and indacaterol 376
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 376
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 376
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 375
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 375
Comorbidities of asthma 375
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 374
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 374
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 373
Biomarkers of lung damage associated with tobacco smoke in induced sputum 372
Influence of ethnicity on response to asthma drugs 370
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 369
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 369
Defining Phenotypes in COPD: An Aid to Personalized Healthcare 367
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 366
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 363
Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure 362
Indacaterol for the treatment of chronic obstructive pulmonary disease 361
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives 361
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 361
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections 359
null 359
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD 358
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients 357
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease 351
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 350
Diabetes mellitus among outpatients with COPD attending a university hospital. 349
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 349
Treating systemic effects of COPD 348
Cardiovascular disease in patients with COPD 347
β2-Agonist Therapy in Lung Disease 345
The clinical use of regenerative therapy in COPD 344
Adherence to COPD treatment: Myth and reality 338
Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved 337
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 336
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism 335
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease 331
Biomarkers in COPD 329
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids 328
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 328
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma 327
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis 326
Dual bronchodilation and exacerbations of COPD 326
Inhaled corticosteroids for chronic obstructive pulmonary disease 324
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease 324
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? 321
An update on bronchodilators in Phase I and II clinical trials 319
Novel glucocorticoid receptor agonists in the treatment of asthma 318
Totale 38.473
Salva come PNG Salva come JPEG
Categoria #
all - tutte 140.570
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.570
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.974 0 0 0 0 0 0 1.578 1.662 1.531 1.268 884 1.051
2020/20219.039 908 1.090 953 1.035 872 830 1.237 831 314 297 485 187
2021/20222.318 153 225 72 55 77 259 145 109 133 271 159 660
2022/20232.704 350 152 54 322 244 668 251 172 237 19 163 72
2023/2024908 198 28 69 12 85 214 61 38 16 35 17 135
2024/20252.924 218 1.358 624 322 187 209 6 0 0 0 0 0
Totale 60.667